Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jan;25(1):17–21. doi: 10.1111/j.1365-2125.1988.tb03276.x

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

R R Weber 1, C E McCoy 1, J A Ziemniak 1, E D Frederickson 1, L I Goldberg 1, M B Murphy 1
PMCID: PMC1386609  PMID: 2897206

Abstract

1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.

Full text

PDF
20

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison N. L., Dubb J. W., Ziemniak J. A., Alexander F., Stote R. M. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther. 1987 Mar;41(3):282–288. doi: 10.1038/clpt.1987.29. [DOI] [PubMed] [Google Scholar]
  2. Boppana V. K., Heineman F. C., Lynn R. K., Randolph W. C., Ziemniak J. A. Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1984 Dec 28;317:463–474. doi: 10.1016/s0021-9673(01)91686-3. [DOI] [PubMed] [Google Scholar]
  3. Carey R. M., Stote R. M., Dubb J. W., Townsend L. H., Rose C. E., Jr, Kaiser D. L. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest. 1984 Dec;74(6):2198–2207. doi: 10.1172/JCI111646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gomeni R. PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med. 1984;14(1):25–34. doi: 10.1016/0010-4825(84)90017-9. [DOI] [PubMed] [Google Scholar]
  5. Hahn R. A., Wardell J. R., Jr, Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther. 1982 Nov;223(2):305–313. [PubMed] [Google Scholar]
  6. Hughes A., Thom S., Martin G., Redman D., Hasan S., Sever P. The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol. 1986 Nov;22(5):535–540. doi: 10.1111/j.1365-2125.1986.tb02932.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Stote R. M., Dubb J. W., Familiar R. G., Erb B. B., Alexander F. A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther. 1983 Sep;34(3):309–315. doi: 10.1038/clpt.1983.173. [DOI] [PubMed] [Google Scholar]
  8. Ventura H. O., Messerli F. H., Frohlich E. D., Kobrin I., Oigman W., Dunn F. G., Carey R. M. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation. 1984 Jun;69(6):1142–1145. doi: 10.1161/01.cir.69.6.1142. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES